Collectively, these in vivo experimental data support that the SMNP vectors can be utilized to deliver CRISPR/Cas9 gene editing system and dDNA using the HITI strategy, enabling CRISPR/Cas9‐mediated knockin of intact RS1 gene in retina as a potential nonviral therapeutic solution for treating XLRS. The gene discussed is RS1; the disease is X-linked retinoschisis.